report increas convict compani
connect care strategi continu drive market share
gain higher rate high-margin resuppli sale
ow expect long durat growth support larg instal base
resuppli sale iv on-going oper leverag near term see two
headwind row devic segment growth low cycl period
benefit favor reimburs chang ii ep dilut verili
propel health
point report global mask sale acceler
constant fx outpac global devic sale contribut
higher gm vs pcp ii row devic constant fx weaker
expect hinder favor reimburs chang
boost compar period iii ep dilut invest broadli
line expect
differ see less gm pressur past year
us reimburs stabl least jan though watch
news flow regard new us competit bid rate ii upsid
penetr copd market via portabl oxygen concentr
propel long term iii recoveri row devic
high growth period lap concomit higher resuppli sale
softwar invest underpin long-term growth expertis patient
connect within osa ecosystem born fruit patient complianc
improv resuppli move higher demonstr us mask/oth
revenu growth highest growth sinc deliv
propel health near-term dilut may open copd market
lead downstream referr inhal patient poc/vent diseas
progress verili health jv also near-term dilut may lead higher
diagnosi rate osa suffer support long-term cpap devic growth
valuat sit vs coverag remain confid long-term
growth potenti remain ow still prefer stock trade
ep vs australian off-shore growth earner ew-rat
ep
up/downsid price target
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
exhibit statist resm cdi
price target convert cdi
cdi disclaim end report morgan stanley research
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
analyst employ non-u affili regist
finra may associ person member may
subject nasd/nys restrict commun
subject compani public appear trade secur held
rate ow market share gain
wide dispers outcom exist
wide dispers outcom exist
equival base case dcf
us devic growth higher current forecast addit small move
mask turn see upsid poc reach share
appli dcf valuat forecast includ step us
growth rate associ new product launch decay pa long
bear case assum reduct us mask price reduct us unit
growth remain intern level pa poc remain
increas instal base support
futur posit momentum sale
consum enhanc confid
long-term sustain ep growth
product launch without rmd
top line would revert market growth rate
fewer price declin pa
weather cost increas line cpi
growth rate possibl owe
under-penetr osa suffer co-
high growth high-margin
therapi repeat mask/dispos sale
occur
upsid at-hom diagnosi de-
bottleneck clinic pathway
data uptak competitor next-
traction upcom launch three new
advers impact us competit bid
continu loss cpap market share
eur usd continu deterior
exhibit bear bull device/mask asp gm biggest valu driver
risk achiev price
ask turn
ask turn
pressur
next
result review
us beat devic sale grew vs mse mask vs
mse saa revenu ahead mse
row miss devic revenu vs mse cc basi
compar cc growth complet devic upgrad
program japan franc continu affect sale mask vs mse
gp margin improv behind mse gp margin mse
due higher-margin contribut matrixcar off-set declin asp
gp margin guidanc better mse fell sale
better mse sale mse expect
sale mse sale mse
ep beat con miss mse non-gaap ep slightli
behind mse due higher tax rate vs mse ebit
compani data morgan stanley research estim mse account verili cost pre-tax profit number adjust show like-for-lik basi
chang forecast
us devic sale move slightli expect
us mask sale assum
continu take market share given strong result
row devic sale mask move lower slightli
provid guidanc gp margin sg updat
model captur
tax rate guidanc assum previous
small chang ep driven chang show forecast
exhibit chang estim follow
compani data morgan stanley research account verili cost pre-tax profit number adjust show like-for-lik basi
view longer-term-depend dcf valuat methodolog
appropri employ determin forward price
target increas due small posit
earn revis longer term bull bear case valuat
increas due higher base case valuat bull case
bear case
main dcf assumpt unchang shown exhibit exhibit
debt
equiti
npv cashflow
valu equiti
share issu
price target convert cdi
investor awar calcul take account
issu risk associ invest adr includ limit
liquid vote right dividend volatil currenc exchang rate
cdi base case move due higher rmd base
march center medicar medicaid servic releas detail
next round competit bid round round take place
competit bid area cba across us total product
categori follow announc last year juli saw expiri
contract decemb next round begin know
commenc onward
background chang announc see inc risk
soften better volum price like first impress jul
updat timelin round
juli bidder registr period bid window open day
win price lead item categori
januari implement contract price
discuss key chang round
lead item price use first time competit bid round lead
item price bid mechan requir supplier submit singl bid
product categori cms-specifi lead item singl payment amount
spa product non-lead item within categori calcul
lead item price cms-specifi rel ratio
product categori establish product categori cover
product durabl medic equip prosthet orthot suppli
dmepo competit bid program main categori relev
continu posit airway pressur devic respiratori assist devic categori
includ sleep-relev product
lead item lead item product highest total allow charg
establish bid limit ceil lead item cpap devic
categori lead item cpap devic hcpc code maximum
allow bid note limit vari state
non-lead item releas rel ratio use calcul non-lead item price
rel ratio cpap devic categori shown exhibit
implic methodolog mean price increas lead item
correspond increas across product instead price may
higher other lower compar previou reimburs rate
rel ratio non-lead item rel ratio base fee schedul
differ lead vs non-lead item accord ratio deriv
divid averag histor unadjust fee schedul amount area
non-lead item averag histor unadjust fee schedul amount area
lead item last unadjust year
scenario analysi ran scenario highlight result non-lead item bid
differ lead item bid amount within cpap devic categori show
bid cpap devic lead item repres increas
cpap devic reimburs rate howev rang price chang
humidifi tube
implic bid supplier choos submit highli depend
individu busi mix exampl sleep durabl medic equip dme
sale skew devic resuppli may will submit lower bid
supplier higher exposur resuppli
exhibit lead item price requir bidder submit singl bid amount cpap devic bid item within sleep
respiratori assist devic product categori rang potenti lead item bid shown result price item within
bid amount lead item us mn
tube heat element
nasal cannula type mask
exhibit product categori lead item round
continu posit airway pressur cpap devic respiratori assist devic rad
oxygen oxygen equip
patient lift seat lift
support surfac group
scenario analysi lead item price current bid rate
wish see could estim financi impact industri lead
item price post bid process equat current rate new
rel ratio shown exhibit compar ratio impli
current bid rate gener alway may indic lower reimburs
exhibit differ new cb rel ratio impli ratio former floor ceil
tube heat element
nasal cannula type mask
recent avail data us medicar expenditur relev
hcpc code shown exhibit
exhibit latest us medicar data expenditur sleep-rel hcpc code us
tube integr heat element use posit airway pressur devic
combin oral/nas mask use continu posit airway pressur devic
oral cushion combin oral/nas mask replac
nasal pillow combin oral/nas mask replac pair
full face mask use posit airway pressur devic
face mask interfac replac full face mask
cushion use nasal mask interfac replac
pillow use nasal cannula type interfac replac pair
nasal interfac mask cannula type use posit airway pressur devic without
headgear use posit airway pressur devic
chinstrap use posit airway pressur devic
tube use posit airway pressur devic
filter dispos use posit airway pressur devic
filter non dispos use posit airway pressur devic
chamber humidifi use posit airway pressur devic replac
respiratori assist devic bi-level pressur capabl without back-up rate featur use
non-invasive interfac nasal facial mask intermitt assist devic continu
respiratori assist devic bi-level pressur capabl without back-up rate featur use
non-invasive interfac nasal facial mask intermitt assist devic continu
respiratori assist devic bi-level pressur capabl back-up rate featur use
non-invasive interfac nasal facial mask intermitt assist devic continu
humidifi non-heat use posit airway pressur devic
humidifi non-heat use posit airway pressur devic
humidifi heat use posit airway pressur devic
humidifi heat use posit airway pressur devic
averag amount medicar paid supplier deduct
coinsur amount deduct line item dmepo
product/servic total supplier medicar payment amount
calcul multipli averag supplier medicar payment
amount number supplier servic
averag amount medicar paid beneficiari deduct
coinsur amount deduct line item
dmepo product/servic standard medicar
payment appli standard remov geograph
differ payment rate individu product/servic
note variabl avail start calendar year
adjust current averag supplier medicar payment amount averag
supplier medicar standard payment amount shown exhibit
 assum lead item price remain
 appli cb new rel ratio
estim theoret medicar expenditur sleep hcpc code
exhibit scenario us sleep expenditur assum lead item price constant
appli new cb ratio us
tube integr heat element use posit airway pressur devic
combin oral/nas mask use continu posit airway pressur devic
oral cushion combin oral/nas mask replac
nasal pillow combin oral/nas mask replac pair
full face mask use posit airway pressur devic
face mask interfac replac full face mask
cushion use nasal mask interfac replac
pillow use nasal cannula type interfac replac pair
nasal interfac mask cannula type use posit airway pressur devic without
headgear use posit airway pressur devic
chinstrap use posit airway pressur devic
tube use posit airway pressur devic
filter dispos use posit airway pressur devic
filter non dispos use posit airway pressur devic
chamber humidifi use posit airway pressur devic replac
respiratori assist devic bi-level pressur capabl without back-up rate featur use
non-invasive interfac nasal facial mask intermitt assist devic continu
respiratori assist devic bi-level pressur capabl without back-up rate featur use
non-invasive interfac nasal facial mask intermitt assist devic continu
respiratori assist devic bi-level pressur capabl back-up rate featur use
non-invasive interfac nasal facial mask intermitt assist devic continu
humidifi non-heat use posit airway pressur devic
humidifi non-heat use posit airway pressur devic
humidifi heat use posit airway pressur devic
humidifi heat use posit airway pressur devic
scenario lead item price constant medicar expenditur would
increas averag supplier medicar payment amount averag
exhibit scenario chang medicar expenditur appli new ratio data
tube integr heat element use posit airway pressur devic
combin oral/nas mask use continu posit airway pressur devic
oral cushion combin oral/nas mask replac
nasal pillow combin oral/nas mask replac pair
full face mask use posit airway pressur devic
face mask interfac replac full face mask
cushion use nasal mask interfac replac
pillow use nasal cannula type interfac replac pair
nasal interfac mask cannula type use posit airway pressur devic without
headgear use posit airway pressur devic
chinstrap use posit airway pressur devic
tube use posit airway pressur devic
filter dispos use posit airway pressur devic
filter non dispos use posit airway pressur devic
chamber humidifi use posit airway pressur devic replac
respiratori assist devic bi-level pressur capabl without back-up rate featur use
non-invasive interfac nasal facial mask intermitt assist devic continu
respiratori assist devic bi-level pressur capabl without back-up rate featur use
non-invasive interfac nasal facial mask intermitt assist devic continu
respiratori assist devic bi-level pressur capabl back-up rate featur use
non-invasive interfac nasal facial mask intermitt assist devic continu
humidifi non-heat use posit airway pressur devic
humidifi non-heat use posit airway pressur devic
humidifi heat use posit airway pressur devic
humidifi heat use posit airway pressur devic
overal effect posit note mani resuppli item neg
scenario highlight need educ disciplin bid process
encourag element new bid process sureti bond
bid win rang spa lead item singl payment amount spa
exhibit singl payment amount spa would base
maximum bid within win bid rang
lead item maximum bid submit item supplier whose bid
item win rang competit bid area product
win rang win bidder whose lead item
bid equal pivot bid product
categori cba pivot bid clear price
lead-item bid base bid submit supplier product
categori includ suffici number supplier meet
beneficiari demand item categori
implic gener support higher price els
equal singl payment amount taken highest bid
win rang compar medium price
previou method chang also mean win bidder
award contract price either bid
rather possibl lower price median bid
price methodolog seen previou round
bid sureti bond bidder must obtain bond
certifi compani area bid bidder award contract
bid median bid within win bid rang use
determin spa supplier fulfil contract bond
implic like discourag low ball bid issu previou
round previous supplier could submit low bid intent fulfil
contract creat lower price competitor cba
profit loss
growth pcp
growth pcp
abn extra tax
return asset
return equiti
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
growth pcp
fy sale
 fy ebit
dep amort
gross cash op ns
inc dec wk cap
chg loan
net chg cash
note provid research coverag list cdi associ underli ordinari share compani courtesi may includ cdi price target cdi share price aud
dollar research report unless otherwis state cdi price target convers calcul use appropri currenc exchang rate ordinari share versu cdi ratio investor awar
calcul take account issu risk associ invest cdi includ limit liquid vote right dividend volatil currenc exchang rate fluctuat
price target deriv base-cas scenario dcf
assum wacc termin growth rate
potenti announc acquisit biotech/vaccines/immunolog
ii industri de-stock possibl price increas
iii uptak kcentra us
lower-than-expect adopt next-gener rcoag product
ii appreci aud usd
iii chang us reimburs environ
price target deriv base-cas scenario dcf
assum wacc termin growth rate
risk achiev price target
upsid faster roll-out nucleu profil weaken higher
penetr upgrad market
downsid reimburs restrict us develop eu strengthen
disappoint uptak new product
